Gonadotropin-releasing hormone antagonist: how good is the new hope?

被引:11
作者
Albano, C [1 ]
Platteau, P [1 ]
Devroey, P [1 ]
机构
[1] Dutchspeaking Brussels Free Univ, Ctr Reprod Med, B-1090 Brussels, Belgium
关键词
D O I
10.1097/00001703-200106000-00002
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Gonadotropin-releasing hormone agonists have been widely used to prevent luteinizing hormone surges during controlled ovarian stimulation in assisted reproductive technologies. Treatment with gonadotropin-releasing hormone agonists of uterine myoma, endometriosis and some hormone-dependent cancers, such as breast, ovarian, endometrial and prostate cancer, also seems to have a beneficial effect. Gonadotropin-releasing hormone agonists have the disadvantage of inducing an initial stimulatory effect on gonadotropin secretion, necessitating 2-3 weeks before pituitary desensitization is achieved, Gonadotropin-releasing hormone antagonists, on the contrary, cause an immediate inhibition of gonadotropin secretion by competitive blocking of pituitary gonadotropin-releasing hormone receptors. Some advantages of their clinical use in controlled ovarian stimulation have already been demonstrated. Randomized comparative studies are needed to investigate their benefit over gonadotropin-releasing hormone antagonists for myoma and hormone-related disorders. Curr Opin Obstet Gynecol 13:257-262. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:257 / 262
页数:6
相关论文
共 52 条
[1]   Addition of GnRH antagonist in cycles of poor responders undergoing IVF [J].
Akman, MA ;
Erden, HF ;
Tosun, SB ;
Bayazit, N ;
Aksoy, E ;
Bahceci, M .
HUMAN REPRODUCTION, 2000, 15 (10) :2145-2147
[2]   Ovarian stimulation with HMG:: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin [J].
Albano, C ;
Felberbaum, RE ;
Smitz, J ;
Riethmüller-Winzen, H ;
Engel, J ;
Diedrich, K ;
Devroey, P .
HUMAN REPRODUCTION, 2000, 15 (03) :526-531
[3]   Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation [J].
Albano, C ;
Smitz, J ;
Camus, M ;
RiethmullerWinzen, H ;
VanSteirteghem, A ;
Devroey, P .
FERTILITY AND STERILITY, 1997, 67 (05) :917-922
[4]  
[Anonymous], 1998, Hum Reprod, V13, P3023
[5]  
Borm G, 2000, HUM REPROD, V15, P1490
[6]  
Chatzaki E, 1996, CANCER RES, V56, P2059
[7]   A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix [J].
de Jong, D ;
Macklon, NS ;
Fauser, BCJM .
FERTILITY AND STERILITY, 2000, 73 (05) :1051-1054
[8]   SUPPRESSION OF THE ENDOGENOUS LUTEINIZING-HORMONE SURGE BY THE GONADOTROPIN-RELEASING-HORMONE ANTAGONIST CETRORELIX DURING OVARIAN STIMULATION [J].
DIEDRICH, K ;
DIEDRICH, C ;
SANTOS, E ;
ZOLL, C ;
ALHASANI, S ;
REISSMANN, T ;
KREBS, D ;
KLINGMULLER, D .
HUMAN REPRODUCTION, 1994, 9 (05) :788-791
[9]  
EDWARDS RG, 1983, LANCET, V2, P1265
[10]  
Emons G, 1996, CANCER, V78, P1452